The stock of Nantkwest Inc (NASDAQ:NK) is a huge mover today! The stock increased 5.14% or $0.38 during the last trading session, hitting $7.78. About 201,599 shares traded hands. Nantkwest Inc (NASDAQ:NK) has declined 0.13% since February 26, 2016 and is downtrending. It has underperformed by 10.56% the S&P500.
The move comes after 6 months positive chart setup for the $605.99 million company. It was reported on Oct, 1 by Barchart.com. We have $12.06 PT which if reached, will make NASDAQ:NK worth $333.29 million more.
Analysts await Nantkwest Inc (NASDAQ:NK) to report earnings on November, 10. They expect $-0.38 EPS, up 30.91% or $0.17 from last year’s $-0.55 per share. After $-0.41 actual EPS reported by Nantkwest Inc for the previous quarter, Wall Street now forecasts -7.32% EPS growth.
Nantkwest Inc (NASDAQ:NK) Ratings Coverage
Out of 7 analysts covering NantKwest (NASDAQ:NK), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. NantKwest has been the topic of 8 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Citigroup maintained Nantkwest Inc (NASDAQ:NK) rating on Monday, March 14. Citigroup has “Neutral” rating and $10 price target. The company was initiated on Monday, August 24 by Citigroup. The rating was initiated by Jefferies with “Buy” on Monday, August 24. The firm has “Buy” rating given on Monday, August 24 by MLV. The stock of Nantkwest Inc (NASDAQ:NK) has “Outperform” rating given on Wednesday, October 28 by FBR Capital. The firm has “Overweight” rating by Piper Jaffray given on Monday, August 24. On Thursday, June 2 the stock rating was initiated by Raymond James with “Market Perform”. Canaccord Genuity initiated Nantkwest Inc (NASDAQ:NK) rating on Tuesday, December 22. Canaccord Genuity has “Buy” rating and $20 price target.
According to Zacks Investment Research, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California.”
More notable recent Nantkwest Inc (NASDAQ:NK) news were published by: Latimes.com which released: “LA billionaire Soon-Shiong gets $148-million payday even as his firm’s stock tanks” on April 28, 2016, also Fool.com with their article: “Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals” published on June 28, 2016, Fool.com published: “Why NantKwest, Inc.’s Shares Briefly Stumbled Today” on March 11, 2016. More interesting news about Nantkwest Inc (NASDAQ:NK) were released by: Wsj.com and their article: “NantKwest Gives Biotech Another Big IPO” published on July 28, 2015 as well as Prnewswire.com‘s news article titled: “Shareholder Class Action Filed Against NantKwest, Inc. – NK” with publication date: March 24, 2016.
NK Company Profile
NantKwest, Inc., formerly Conkwest, Inc., incorporated on March 12, 2014, is a biotechnology company, which is engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Firm is a clinical-stage immunotherapy firm focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Company’s NK cell platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action, such as direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact; antibody-mediated killing using high-affinity NKs (haNKs), which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and targeted activated killing using target activated Natural Killers (taNKs), which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.